The approved variation enables Upperton to commence GMP manufacture of sterile investigational medicinal products from the purpose-built facility, expanding the company’s integrated development and ...

Decisions around trial design, regulatory strategy, and manufacturing planning ultimately determine whether a therapy reaches patients.

This week on "The Friday Brief," companies put down roots on both sides of the Atlantic, expanding their capabilities in a number of areas.

Neuland Laboratories has officially launched the first module of its commercial peptide manufacturing facility in Hyderabad, ...

Shilpa Biologicals Private Limited has entered into an exclusive strategic licensing and commercialization agreement with ...

Serialization planning, data visibility and partner connectivity can help biopharma companies prepare complex therapies for ...

Of that new CDMO capacity, 71% by volume is large-scale stainless steel, she said, but this is being installed by just a ...

Highly potent active pharmaceutical ingredients are no longer a niche manufacturing challenge reserved for a limited set of ...

Formulation of high dose large molecules like proteins and biologics for injectables has created a great opportunity for ...

This week on "The Friday Brief," facility news in the United States and abroad outshined the partnerships announced.

Soobin Han of Marken, UPS Healthcare Precision Logistics discusses an evolution in APAC, from clinical trials to cold chain ...

Shilpa CD MO, a dedicated complex small-molecule contract development and manufacturing organization is launching at CPHI Milan. The new brand, separate from parent company Shilpa Medicare, provides a ...